Protagonist CEO gifts 510 shares to relatives

PTGX’s CEO and director reported a bona fide gift of common stock to relatives, with over half a million shares still held directly.

Rhea-AI Filing Summary

Protagonist Therapeutics, Inc (PTGX) reported that President and CEO and director Dinesh V. Patel, Ph.D., made a bona fide gift transfer of 510 shares of Common Stock on September 3, 2026. The shares were gifted to relatives, and he now directly holds 522,968 shares of Protagonist Therapeutics common stock.

Insider Trade Summary

510 shares gifted

Gift 1 txn

Insider PATEL DINESH V PH D

Role President and CEO

Type	Security	Shares	Price	Value
Gift	Common Stock F1	510	$0.00	$0.00

Holdings After Transaction: Common Stock — 522,968 shares (Direct)

Footnotes (1)

1. F1. This transaction involves a bona fide gift of securities from the Reporting Person to relatives.

Key Figures

Shares gifted: 510 shares Transaction price per share: $0.00 per share Shares held after transaction: 522,968 shares

3 metrics

Shares gifted 510 shares Bona fide gift of Protagonist Therapeutics common stock on September 3, 2026

Transaction price per share $0.00 per share Reported for the bona fide gift transaction

Shares held after transaction 522,968 shares Direct holdings of Dinesh V. Patel, Ph.D., after the gift

Key Terms

bona fide gift, Common Stock, Rule 10b5-1

3 terms

bona fide gift financial

"This transaction involves a bona fide gift of securities from the Reporting Person"

A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.

Common Stock financial

"The transaction involved Protagonist Therapeutics, Inc. Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Rule 10b5-1 regulatory

"The filing’s Rule 10b5-1 checkbox is not affirmed"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

What insider transaction did PTGX report for Dinesh V. Patel, Ph.D.?

The company reported that Dinesh V. Patel, Ph.D., its President, CEO, and director, made a bona fide gift of 510 shares of Protagonist Therapeutics common stock on September 3, 2026.

How many PTGX shares were involved in the reported gift?

The transaction involved a gift of 510 shares of Protagonist Therapeutics common stock. The filing classifies it as a bona fide gift, not a sale, with a reported transaction price of $0.00 per share.

Who received the gifted PTGX shares from the CEO?

According to the filing’s footnote, the transaction is a bona fide gift of securities from the reporting person to relatives. No specific relatives are named, only that the recipients are family members.

How many PTGX shares does Dinesh V. Patel hold after the gift?

After the reported gift transaction, Dinesh V. Patel, Ph.D., directly holds 522,968 shares of Protagonist Therapeutics common stock, as stated in the post-transaction holdings figure.

Was the PTGX insider gift made under a Rule 10b5-1 trading plan?

No. The filing’s Rule 10b5-1 checkbox is not affirmed, and there is no footnote indicating that this bona fide gift of 510 shares was made pursuant to a Rule 10b5-1 or other pre-arranged trading plan.

Does the PTGX CEO’s transaction represent a sale of shares?

No. The transaction is identified with code G as a bona fide gift and not a sale. The filing lists the transaction price per share as $0.00, consistent with a non-sale transfer of shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 05:14 PM Accepted by SEC EDGAR 09/08/2026 - 05:14 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PATEL DINESH V PH D

(Last) (First) (Middle)

C/O PROTAGONIST THERAPEUTICS, INC.

7707 GATEWAY BLVD., SUITE 140

(Street)

NEWARK CALIFORNIA 94560-1160

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Protagonist Therapeutics, Inc [ PTGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/03/2026		G(1)		510	D	$0.00	522,968	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction involves a bona fide gift of securities from the Reporting Person to relatives.

	/s/ Matthew Gosling, Attorney-in-Fact for Dinesh V. Patel, Ph.D.	09/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)